Antidepressant Pipeline: A Wave of Innovation and Investment

2023Year8Month, the first and only one for adult postpartum depression (PPD）Oral therapeutic drugsZurzuvae（Zuranolone) Approved for Marketing in the U.S., Broadening the Patient Population for Depression Treatment.

2025Year1In the month, Johnson & Johnson announced a total transaction value of approximately146Billion-dollar acquisitionIntra-Cellular Therapies`, the company`Core Product is5-Serotonin2A（5-HT2A) Receptor Antagonist and Dopamine ReceptorD2ModulatorCaplyta(Lumateperone,Lumateperone），CaplytaObtainedFDAApproved for the treatment of adult schizophrenia and bipolar disorder.IType orIIDepressive Episodes Associated with Type Disorders。

2025Year8Month, AbbVie withUp to12Acquisition for $ billionGilgamesh PharmaceuticalsAntidepressant drugs under its umbrellabretisilocin, the drug is currently in clinical2Period.

TheseApproval of New Mechanism Drugs andBlockbuster deals show the pharmaceutical industry's emphasis and investment in the field of depression treatment, also reflecting the market's urgent demand for new and more effective antidepressant drugs.

Epidemiology of Depression

Depression is a common mental disorder, mainly characterized by symptoms such as low mood, loss of interest, slowed thinking, and physical discomfort. It not only affects the patient's quality of life but may also have a negative impact on work, study, and social functioning.

According to2021Global Burden of Disease Study, Global Depression Incidence3.5744100 million cases, with the number of patients being3.3241100 million cases, Disability-Adjusted Life Years (DALYs) for5633Million. Depression is a major public health challenge worldwide, with its incidence, prevalence, andDALYsAlthough the age-standardized rate shows a declining trend, the absolute number of cases and the age-standardized rate are still increasing.[1]。

Major depressive disorder is one of the most common mental disorders in the United States. For some people, major depressive disorder can lead to severe impairment, interfering with or limiting one’s ability to carry out major life activities.

2021Year, it is estimated that there are2100Million adults have experienced at least one major depressive episode, accounting for all American adults.8.3%. Among them, the incidence rate in women is10.3%, higher than that of males6.2%，18-25The incidence rate in the age group is18.6%, which is the highest across all age groups., inAmong populations with multiple (two or more) racial identities, the incidence rate of major depressive episodes is the highest, at13.9%(Figure1）[2]。

Figure1. 2021Year America18Prevalence of Major Depressive Episodes in Adults Aged 18 or Older in the Past Year

It is estimated that there are500Ten Thousand12To17Teenagers aged 12 to 17 have experienced at least one major depressive episode. This figure accounts for the United States.12To17Population by Age20.1%。

Compared with men (11.5%) compared to adolescent females (29.2%) had a higher prevalence of major depressive episodes.
The prevalence of major depressive episodes is highest among adolescents of two or more races (27.2%）。

Figure2. 2021 Prevalence of Major Depressive Episodes in U.S. Adolescents in the Past Year

According to the China Mental Health Survey (CMHS) shows that the lifetime prevalence of depression in China is6.8%，12Monthly prevalence rate is3.6%. This means more than9500100 million Chinese people have suffered from depression at some point in their lives. The lifetime prevalence of depression among women is8.0%, significantly higher than that of males5.7%[3]。

Pathogenesis of Depression

So far, the pathogenesis of depression has attracted an increasing number of researchers worldwide to explore, but the exact mechanism remains unclear. The receptor hypothesis has been used to elucidate the pathogenesis of depression from multiple perspectives.[1]。

In addition to well-known receptors, such asNMDAReceptor,AMPAReceptor, Glucocorticoid Receptor,5-HTReceptor,GABAReceptor andDAIn vitro,“Non-classical”Receptors, such as metabotropic glutamate receptors, opioid receptors, and insulin receptors, are also important in the pathogenesis of depression.(Figure1）。

Moreover, a large number of studies have shown that the occurrence and development of depression are closely related to the genetic basis, which accounts for nearly 40-50%, making depression a highly heritable disease and drawing broader attention.

Due to depression (MDD) has a complex pathogenesis, and accurate diagnostic methods and drug treatment strategies are relatively limited. To explain the pathogenesis of depression, several hypotheses have been proposed, including: (i) Hypothalamus-Pituitary-Adrenal (HPA) Axis Dysfunction Hypothesis, (ii) Monoamine Hypothesis, (iii) Inflammation Hypothesis, (iv) Hypothesis of genetic and epigenetic abnormalities, (v) Hypothesis of brain structure and function remodeling, and (vi) Social Psychological Hypothesis(Figure3）[4]。

Figure3. Pathogenesis of Depression

HPAThe Axis Dysfunction Hypothesis suggests that the occurrence of depression is related toHPAThe excessive activation of the axis and the impairment of the negative feedback mechanism are closely related. This dysfunction leads toGCAbnormally elevated levels subsequently affect the activity of neurotransmitters and neurotrophic factors, ultimately leading to the onset of depression.。

The monoamine hypothesis is one of the classical theories explaining the pathogenesis of depression.,The monoamine hypothesis suggests that the occurrence of depression is related to the deficiency of monoamine neurotransmitters in the brain, primarily including5-Serotonin (5-HT, Serotonin) Norepinephrine (NE）、Dopamine (DA）Neurotransmitters such as。

Many antidepressant drugs work by increasing the levels of monoamine neurotransmitters in the brain. For example, selective5-Serotonin Reuptake Inhibitors (SSRIs) By inhibiting5-HTReuptake, increasing the synaptic cleft5-HTThe concentration, thereby improving depressive symptoms. Tricyclic antidepressants (TCAs) while simultaneously inhibiting5-HTAndNEReuptake. The efficacy of these drugs supports the monoamine hypothesis.

However, no single hypothesis can adequately explain depression (MDD) as the pathological basis, and many mechanisms proposed by these hypotheses interact with each other. In recent years, significant progress has been made in identifying new drug therapies, diagnostic criteria, and non-pharmacological preventive measures for depression, and relevant clinical trials have been initiated. Specifically, an increasing amount of evidence suggests that astrocyte dysfunction plays an important role in depression. In experimental animals, pharmacological ablation of the medial prefrontal cortex (mPFC) Astrocytes in the prefrontal cortex can lead to depression-like symptoms, and autopsy studies of patients with depression show that their prefrontal cortex (PFC), and the density of glial cells in the hippocampus and amygdala was reduced.

Approved Antidepressant Drugs

There are already multiple drugs on the market globally, but currently, there is poor consistency in the drug treatment recommendations outlined in depression treatment guidelines around the world, particularly in the United States.Commonly Used12A type of antidepressant includes selective5-Serotonin Reuptake Inhibitors (SSRIs）、5-Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs`) and atypical antidepressants.`

These drugs are: Sertraline (Zoloft), Escitalopram (Lexapro), Trazodone, Fluoxetine (Prozac), Bupropion (Wellbutrin), Duloxetine (Cymbalta), Quetiapine (Seroquel), Citalopram (Celexa), Venlafaxine (Effexor), Aripiprazole (Anlifan), paroxetine (Paroxetine), and mirtazapine (Remeron). These drugs are commonly used to treat major depressive disorder and related conditions due to their significant efficacy and varying side effects, allowing clinicians to tailor treatment plans according to individual patient needs.[5]。

GlobalCommonly Used Antidepressant Drugs IncludeLundbeck's escitalopram, Pfizer's sertraline, AbbVie's fluvoxamine,GSKParoxetine, Eli Lilly's Duloxetine, and Wyeth'sWenLafaxin, etc.。

In recent years, several novel antidepressant drugs with innovative mechanisms have been approved for marketing.。

2019Year3In the month, esketamine nasal spray was approved for the first time in the United States.FDAApproval for the treatment of refractory depression (TRD), need to be used in combination with oral antidepressants。

Esketamine (Esketamine) is the dextrorotatory isomer of ketamine, with higher potency.，By blockingNMDAReceptor, increase the release of glutamate, activateAMPAReceptor, promoting neurotrophic factors (such asBDNF), thereby enhancing synaptic plasticity and neuroregeneration.(Figure4）[6]。

Figure4. EsketamineMechanism of Action

EsketamineTheSUSTAIN-3The test results showed:During the induction therapy, Montgomery-Asperger Depression Scale (MADRS) The total score has decreased, and this decrease is optimized/Maintained during the maintenance treatment period (average from baseline of each phase to phase endpoint)[Standard Deviation]Changes: Induction Period:-12.8[9.73]; Optimization/Maintenance Period:+0.2[9.93]). At the end of induction therapy, there35.6%of participants achieved remission; at week112Zhou and Optimization/At the end of maintenance treatment, there were respectively48.5%And49.6%Participants achieved remission(Figure5）[7]。

Figure5. EsketamineTheSUSTAIN-3Test Results

2023Year4Month20The China National Medical Products Administration has officially approved the esketamine hydrochloride nasal spray (brand name: Spravato) produced by Johnson & Johnson for marketing in China.This is the first antidepressant drug approved in China with a novel mechanism of action and route of administration.Mainly used in combination with oral antidepressants, it can quickly alleviate depressive symptoms in adult patients with major depressive disorder accompanied by acute suicidal ideation or behavior.

2025Year1Month21Day,Johnson & Johnson announcedFDAApprovedSPRAVATO®（Esketamine）CIII New Drug Application Supplement for Nasal Spray (sNDA), making this innovative therapy the first and only one targeting major depressive disorder (MDD) patients who have had an inadequate response to at least two oral antidepressants (MDD) Monotherapy for adults.

2022Year8In the month, U.S. biopharmaceutical companyAxsome TherapeuticsAntidepressant Oral MedicationAuvelityObtained in the United StatesFDAApproved for the treatment of adult depression (MDD），Become60The world's first new-mechanism oral antidepressant in many years,Opened a new market in the crowded old antidepressant drug market.

AuvelityIt is a fixed-dose combination sustained-release tablet, with main ingredients including dextromethorphan hydrobromide (45mg) and Bupropion Hydrochloride (105mg），DextromethorphanAsNMDAReceptor Antagonists andσ-1Receptor agonist, modulates glutamatergic neurotransmission, possesses anticonvulsant and neuroprotective effects, and can also block the reuptake of serotonin and dopamine.；BupropionInhibitionCYP2D6Enzymes, prolonging the half-life of dextromethorphan, thereby enhancing its effect.(Figure6）。

Figure6. AuvelityMechanism of Action

Clinical trial data show,AuvelityTreatment for AdultsMDDThe patient experienced rapid onset of effects,Treatment1Weeks can significantly improve depressive symptoms. Treatment2Weeks later, the clinical cure rate significantly improved compared to the placebo and continued until the end of treatment. Safety results showedAuvelityWell Tolerated(Figure7）。

Figure7. AuvelityEfficacy

2023Year8Month4Day, Biogen andSage TherapeuticsCo-developed by the companyNeuroactive Steroidsγ-Aminobutyric AcidAType (GABAA）Receptor Positive Allosteric ModulatorZurzuvae（Zuranolone) ObtainFDAApproved, becoming the first and only treatment for adult postpartum depression (PPD) Oral therapeutic drugs。2025Year7Month24Day, European Medicines Agency (EMA) Human Medicines Committee (CHMP) is also recommended to be grantedZurzuvaeMarketing Authorization。

ZurzuvaeA clinical trial (NCT04442503) The study found that taking it daily Zurzuvae 50 mg, Continuous2Week's women on the15Significant reduction in depressive symptoms during the day.
   Compared with placebo scores,Zurzuvae 50mgThe17Hamilton Depression Rating Scale (HAMD-17) Decreased-15.6（HAMD-17), the placebo score decreased-11.6, the difference is-4.0, depressive symptoms from the 3The day began to improve and continued until the42Day (Fig8）[8]。

Figure8. ZurzuvaeEfficacy

Novel Mechanism Antidepressants Under Research

In addition, there are many new mechanism antidepressant drugs under research, such asOsavampator、Seltorexant、GH-001、NBI-1070770AndJJH201501etc. (Figure9）。

Figure9. Some Approved and Investigational Antidepressant Drugs

Osavampator（NBI-1065845OrTAK-653）Originally developed by Takeda Pharmaceutical Company.AMPAPositive Allosteric Modulator (PAM）。2020Year,Neurocrine BiosciencesObtainedosavampatorAnd exclusive rights to six other neuropsychiatric disease projects, paid1.2Hundreds of millions of dollars in upfront payments. According to the original agreement, Takeda Pharmaceutical is eligible to receive up to4.95USD billion in development milestone payments, up to14USD billion commercial milestone payment, and a net sales share of up to double-digit percentages。2025Year1Month27Day,TakedaRenegotiated the deal, regainedosavampatorExclusive Rights in Japan (Figure10）[9]。

Figure10. OsavampatorStructure

Preclinical studies show:OsavampatorIn the rat forced swimming behavior model (RSBM), after passing through6Significant antidepressant-like effects were observed after daily administration. However, unlike ketamine,TAK-653It did not induce excessive motor behavior in rats, a behavioral indicator associated with schizophrenia-like side effects in humans. Therefore,TAK-653It may be a drug with the potential to improve safety and can be used to treat including treatment-resistant depression (TRD) including severe depression (Fig.11）[10]。

Figure11. OsavampatorPreclinical Study Results

2024Year4Month,NeurocrinePublishedosavampatorIn adultsMDDIn the subjects2PeriodSAVITRI™Positive Topline Data from the Study:AcceptosavampatorThe treated patients on the28Day (Primary Endpoint) and Day56Day (Secondary Endpoint) of Montgomery-Asperger Depression Rating Scale (MADRS) The total score showed statistically significant improvement(Figure12）。

Figure12. OsavampatorClinical Outcomes

This Year1Month28Day,NeurocrineAnnouncing the launch of a3A prospective registration study to evaluateosavampatorEfficacy, safety, and tolerability for major depressive disorder (MDD) Adjunctive Treatment of Antidepressants[11]。

Seltorexant It is a selective orexin developed by Janssen Pharmaceuticals under Johnson & Johnson.-2Receptor (OX2R）Antagonist, aimed at treating major depressive disorder accompanied by insomnia symptoms （MDD) and diseases in the field of neuroscience such as Alzheimer's disease。Johnson & Johnson has currently terminatedseltorexantClinical Research on the Treatment of Alzheimer's Disease, butseltorexantShow Positive Effects in Treating Major Depressive Disorder with Insomnia Symptoms, still ongoing。

2024Year,Mesenset al. in "Molecular Psychiatry》magazine reportedSeltorexantA clinical1bPhase Trial (NCT03374475) Results: A total of128Participants were enrolled, including86Name Enrichment Sample (Non-Responders During Placebo Run-In Period)(Figure13）[12]。

In the5Week, Hamilton Depression Scale17Item (HDRS17) The mean change (standard deviation) in scores from baseline was significantly different between groups:Seltorexant 20mgGroup as-7.0（5.04），Seltorexant 40mgGroup as-5.5（4.34), placebo group was-4.4（3.67）（p=0.0456）`, this difference is attributed to`20mgDifference between the group and the placebo group (p=0.0049）。

In patients with more severe baseline insomnia symptoms,Seltorexant 20mgIn the5At weeks, the improvement in the severity of depression was more significant (nominalp=0.0059). When adjusted by removing sleep itemsHDRSWhen scoring,20mgThe treatment benefits of the group remain significant (nominallyp=0.0289). Compared with the placebo group,20mgGroup'sHDRS17The numerical change in score is greater than40mgGroup, which is consistent with previous research data, in previous studies,SeltorexantIt is administered as an adjunctive drug to traditional antidepressants.

In a secondary analysis,20mgThe cortisol awakening response in the group decreased, while40mgThe group or placebo group did not exhibit such changes; although40mgThe total sleep time of the group increased more, but the group also showed a shortened REM sleep latency andN1Increased sleep duration during the period, and in20mgThis phenomenon was not observed in the group. These biomarker data suggest possible explanations.SeltorexantMechanistic Hypothesis of the Apparent Curve Dose-Response Relationship.

Figure13. SeltorexantClinical1bResults of the Phase Trial

2024Year5Month,Johnson & Johnson announcedseltorexantIn a study targeting patients with major depressive disorder accompanied by insomnia symptomsIIIPhase Clinical Trial (MDD3001) achieved all primary and secondary endpoints. The study showed,seltorexantStatistically and clinically significant in improving depressive symptoms and reducing sleep disturbances(Figure14）[13]。

Figure14. SeltorexantClinical3Results of the Phase Trial

GH001Is byGH Research PLCDeveloped for the treatment of refractory depression (TRD) drug. Its main component is mebiflutine (mefenamic acid，5-MeO-DMT), administered through a proprietary inhalation method.GH001The development aims to activate5-Serotonin2AReceptor (5-HT2A) to produce antidepressant effects (Fig.15）。

Figure15. GH001Clinical Trial Progress

2025Year2Month,GH ResearchAnnouncementGH001A treatment for refractory depression (TRD) Patients' randomized, double-blind, placebo-controlled2bPhase Clinical Trial (GH001-TRD-201) Reached the primary endpoint:GH001In the8Angel Montgomery-Asperger Depression Scale (MADRS) Total score significantly decreased from baseline15.2Points, while the placebo group increased0.3Difference (-15.5Points,p<0.0001）。

All secondary endpoints in the trial were met, with results consistent with the primary endpoint. Compared with placebo,GH001Treatment on Day8Angel Clinician Overall Impression Severity Scale (CGI-S) and Hamilton Anxiety Scale (HAM-A) scores and Quality of Life Questionnaire (Q-LES-Q-SF) were significantly improved, with clinical and statistical significance.[14]。

2025Year7Month,GH ResearchAnnouncing toFDASubmitted for the previously announced GH001 Investigational New Drug Application (IND) Complete response to clinical hold.They have now received FDA The reply, leaving only one reserved issue.。FDAThey were asked to provide additional data or further justification related to the previously published rat respiratory tract histopathology results. They firmly believe, based on scientific evidence, that the histopathology findings are rat-specific. No other requests related to dog toxicology were made. There were no device-related issues. FDA As for IND Complete remission is ongoing. They are actively working to resolve the remaining issues.

GH ResearchPlanned in2026Year LaunchGH001The global pivotal plan is currently in preparation, including the establishment of a steering committee as well as the selection of clinical research organizations and study sites.

BretisilocinIt is developed by a biotechnology company.Gilgamesh PharmaceuticalsDeveloped a5-HT2AReceptor Agonists and5-HTReleasing Agent, by acting on5-HT2AReceptors to exert therapeutic effects,2025Year8In the month, AbbVie Inc.12Billion dollars to acquire the drug (Fig.16）。

Figure16. Gilgamesh PharmaceuticalsTheR&DPipeline

Compared with traditional psychedelic drugs (such asLSDAndpsilocybin) Compared with,BretisilocinWith a shorter half-life, treatment can be completed in about two hours without causing hallucinations.。

2025Year5Month27Day,GilgameshAnnouncedBretisilocinA study targeting patients with severe depression2a Expected Results：Among patients who received two drug treatments,94%The symptoms were significantly relieved after one month. In another2aIn the study, compared with the low-dose control group, Montgomery-Osberg Depression Scale (MADRS) The total score improvement was statistically significant.14Tian Shi, Single Dose (10mg) Treatment GroupMADRSTotal score change from baseline-21.6Points, while low dose (1mg) Control Group Change-12.1Points (p=0.003）(Figure17）。

Figure17. BretisilocinClinical Trial Results

JJH201501It is a vortioxetine derivative developed by Giebel using its deuterated drug R&D technology platform. It is a new type of antidepressant with a multi-receptor mechanism of action. By replacing the methyl hydrogen in vortioxetine with deuterium, the stability of the drug is enhanced, the metabolic rate is slowed down, thereby achieving the purpose of increasing efficacy and reducing adverse drug reactions (Fig.18）。

Figure18. JJH201501Research and Development Progress

JJH201501It has been completed currently.IPeriod,IIaPeriod andIIbPhase Clinical Study。2024Year5Month11Day, hosted by Jibei Pharmaceutical“JJH201501TabletⅢNational Investigator Initiation Meeting for Phase Clinical Research”Successfully Held in Beijing。

At present, new antidepressant drugsJJH201501Are being carried out in an orderly mannerⅢPhase clinical trial, according to the current plan, is expected2025Year CompletedⅢPhase Clinical StudyAnd submit an application for listing。

Luye Pharma Group is an international pharmaceutical company dedicated to the research, development, production, and sales of innovative drugs. Luye Pharma has made significant progress in the research and development of antidepressant drugs, with its core product Roxilitine.®(Toludesvenlafaxine Hydrochloride Extended-Release Tablets) is the first self-developed antidepressant in China with independent intellectual property rights.1Class Innovative Drug, at2022Year12Approved for marketing in (Figure19）。

Roxilitin exerts its effects through a unique triple reuptake inhibition (SNDRI), comprehensively improving depressive symptoms, especially showing significant improvement in anhedonia, psychomotor retardation, and cognitive impairment, overcoming the shortcomings of existing drugs, without causing insomnia or drowsiness, and having no impact on sexual function, weight, or lipid metabolism.。

2025Year8Month18Day,Luye Pharma Group Announces the Use of Roxadustat for the Treatment of Generalized Anxiety DisorderPhase III Clinical Trial Has Completed Patient Enrollment, it is expected that2025Submit for market approval by the end of the year. The trial is a multi-center, randomized, double-blind, placebo-controlled study to evaluate the safety of Ruoxinlin in treating Generalized Anxiety Disorder.

LY03021Developed independently by GreenLeaf Pharmaceutical1Class innovative drug, through targetingNET、DATAndGABAARThree targets work. The product works by acting on the synapses.GABAAReceptor Subtypeα1β2γ2And extrasynapticGABAAReceptor Subtypeα4β3δ, EnhancedGABACorrectGABAAReceptor Activation, Modulation of Glutamate in the Brain-GABACan balance and inhibit the hypothalamus-Pituitary-Adrenal (HPA) Axis Overactivation, Rapidly Exerts Antidepressant Effects.

Non-clinical studies show,LY03021After administration24Significantly improved depressive symptoms in model animals within hours, and continuous administration until21The efficacy is stable, with the advantages of rapid onset and long-lasting effect.。

2025Year8Month3Day,LY03021Conducted in ChinaIPhase Clinical Study Completes First Patient Enrollment。

Figure19. Luye PharmaCNSPipeline

Depression is a common mental health disorder that causes serious harm to patients' physical and mental health as well as social functioning.，Traditional antidepressants play an important role in the treatment of depression, but they have drawbacks such as slow onset, numerous side effects, and significant variability in treatment response. These drawbacks may affect patients' treatment adherence and recovery process., therefore, there is still a need for antidepressant drugs with novel mechanisms.。

As research into the pathogenesis of depression deepens, more and more antidepressant drugs with novel mechanisms are being developed, offering patients a wider range of choices.

PharmCube Media Business Cooperation

Media PR | News &Press Release

Manager Zhang: 18600036371 (Same for WeChat)

Click "PharmSnap" below to follow more exciting content.

The push rules of WeChat Official Accounts have changed again. If you don't tap"Views"Or not set to"Star Mark", we might just dissipate in the vast sea of literature~ Click here, don't miss out on the latest news from PharmaDJ!??